Increased APOBEC3B predicts worse outcomes in lung cancer: A comprehensive retrospective study

Journal of Cancer

Volumn 7, Issue 6, 2016, Pages 618-625

  Yan, Shumei ^a   He, Fan ^b   Gao, Bei ^c   Wu, Huini ^d   Li, Mei ^a   Huang, Liyun ^a   Liang, Jianzhong ^a   Wu, Qiuliang ^a   Li, Yong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

APOBEC3B; Immunohistochemistry; Non small cell lung cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; APOBEC3B ENZYME; CYTOSINE DEAMINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 84976518062     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.14030     Document Type: Article

References (22)

1. Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1: 505-27.
2. Lung cancer diagnosis: when speed wins the day. Lancet Respir Med. 2015; 3: 171.
3. Nowarski R, Kotler M. APOBEC3 cytidine deaminases in double-strand DNA break repair and cancer promotion. Cancer Res. 2013; 73: 3494-8.
4. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013; 45: 977-83.
5. Cescon DW, Haibe-Kains B, Mak TW. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A. 2015; 112: 2841-6.
6. Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer. 2014; 5: 405-13.
7. Feng Y, He F, Wu H, Huang H, Zhang L, Han X, et al. GOLPH3L is a Novel Prognostic Biomarker for Epithelial Ovarian Cancer. J Cancer. 2015; 6: 893-900.
8. Li XH, He F, Yan SM, Li Y, Cao Y, Huang CY, et al. Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study. Med Oncol. 2014; 31: 763.
9. Yan SM, Wu HN, He F, Hu XP, Zhang ZY, Huang MY, et al. High expression of zinc-binding protein-89 predicts decreased survival in esophageal squamous cell cancer. Ann Thorac Surg. 2014; 97: 1966-73.
10. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov. 2015; 5: 704-12.
11. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet. 2014; 46: 487-91.
12. Prohaska KM, Bennett RP, Salter JD, Smith HC. The multifaceted roles of RNA binding in APOBEC cytidine deaminase functions. Wiley Interdiscip Rev RNA. 2014; 5: 493-508.
13. Lada AG, Dhar A, Boissy RJ, Hirano M, Rubel AA, Rogozin IB, et al. AID/APOBEC cytosine deaminase induces genome-wide kataegis. Biol Direct. 2012; 7: 47; discussion
14. Janahi EM, McGarvey MJ. The inhibition of hepatitis B virus by APOBEC cytidine deaminases. J Viral Hepat. 2013; 20: 821-8.
15. Mori S, Takeuchi T, Ishii Y, Kukimoto I. Identification of APOBEC3B promoter elements responsible for activation by human papillomavirus type 16 E6. Biochem Biophys Res Commun. 2015; 460: 555-60.
16. Zhang T, Cai J, Chang J, Yu D, Wu C, Yan T, et al. Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. Hum Mol Genet. 2013; 22: 1262-9.
17. McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015; 7: 283ra54.
18. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013; 494: 366-70.
19. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014; 346: 251-6.
20. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013; 73: 7222-31.
21. Jin Z, Han YX, Han XR. The role of APOBEC3B in chondrosarcoma. Oncol Rep. 2014; 32: 1867-72.
22. Zhang J, Wei W, Jin HC, Ying RC, Zhu AK, Zhang FJ. The roles of APOBEC3B in gastric cancer. Int J Clin Exp Pathol. 2015; 8: 5089-96.